The French company specialises in eCOA solutions for phases IIB/III and has been collaborating with local CRO partners in Japan since 2017
Image as seen on company website
Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) solutions for clinical trials, has opened a subsidiary in Japan, where clinical developments have been expanding. Based in Tokyo, the subsidiary will enable Kayentis to meet the logistical requirements of multi-national studies taking place in AsiaPacific and cater to the needs of local for digital data collection services with custom geographic capabilities.
Kayentis, which specialises in eCOA solutions for phases IIB/III, has been collaborating with local CRO partners in Japan since 2017. As many as 75% of the clinical trial studies conducted by Kayentis include populations from Asia-Pacific.
The decision to establish a permanent presence in the region follows the France-based company's expansion into the US, where it set up a subsidiary in Boston (MA) two years ago. Strengthening Kayentis' global capacity to facilitate client access to its technical expertise, while providing them with high-quality eCOA solutions for studies in Europe, the US and now Asia, has been central to its developments and market positioning.
"The Japanese and the wider Asia-Pacific clinical trials market is important to us. Kayentis already has customers in the region. We are thrilled to be opening a subsidiary in Tokyo, where we will be able to offer closer support to our customers running trials in Asia," said Guillaume Juge, CEO of Kayentis. "This expansion comes amid the release of our eCOA solution - Clin'form3 – available in Japanese. It brings new design improvements that save time during the set-up stages of the study. We anticipate that the easier integration of medical device data and reporting enhancements will be of great benefit to clients in this strategic market."
Richard Triepel, Business Development Director for Asia-Pacific at Kayentis, who has lived and worked in Japan for 14 years, will lead activities at the Tokyo-based subsidiary when it becomes operational in January 2020.
Kayentis will exhibit at the DIA Japan Annual Meeting in Tokyo, November 10 – 12, 2019, at booth #42. DIA is attended by more than 10,000 global participants each year. It is a member-driven organisation that mobilises life sciences and healthcare professionals to collaborate on and problem-solve global and local challenges facing the life sciences community.